Phase 3
Completed N=60
Efficacy of TAP Block in Cesarean Section Patients
Pain Control
Source: ClinicalTrials.gov NCT03493828 ↗
Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Nov 2018
Primary outcomePrimary: Effect of Transversus Abdominis Plane (TAP) Block Using Either 0.5% or 0.25% Bupivacaine on Analgesia for Cesarean Section Patients When Compared to Placebo. — 9.45; 8.95; 17.65 PCA bolus
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
TAP Block done with 2 different concentrations of bupivacaine and placebo
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effect of Transversus Abdominis Plane (TAP) Block Using Either 0.5% or 0.25% Bupivacaine on Analgesia for Cesarean Section Patients When Compared to Placebo. |
9.45; 8.95; 17.65 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy pregnant women
Exclusion Criteria
- Allergy to local anesthetics
Data sourced from ClinicalTrials.gov (NCT03493828). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.